Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507190 | 1.00 | FFAR1 (0.30) | FFAR1GSK3AGSK3BIRAK4MAP3K12 | |
| SCHEMBL25315308 | 1.00 | FFAR1 (0.30) | FFAR1GSK3AGSK3BIRAK4MAP3K12 | |
| SCHEMBL31178330 | 0.83 | CYP1A2 (0.33) | FFAR1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL25924709 | 0.79 | JAK1 (0.33) | MAP3K12 | |
| SCHEMBL25316138 | 0.79 | JAK1 (0.33) | MAP3K12 | |
| SCHEMBL25315214 | 0.79 | PDGFRB (0.33) | FFAR1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL26023725 | 0.79 | PDGFRB (0.33) | FFAR1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL25315066 | 0.78 | CDK9 (0.32) | MAP3K12 | |
| SCHEMBL30506973 | 0.78 | CDK9 (0.32) | MAP3K12 | |
| SCHEMBL26023949 | 0.78 | CDK9 (0.32) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | FFAR1 2388/4885GSK3A 1130/4885GSK3B 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.